4.7 Article

Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases

Journal

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Volume 143, Issue 6, Pages 2095-2107

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2018.11.031

Keywords

Vitiligo; atopic dermatitis; psoriasis; alopecia areata; T(H)1; T(H)2; T(H)17; T(H)22; regulatory T; biomarkers; endotypes

Funding

  1. Abbvie
  2. Celgene
  3. Eli Lilly
  4. Janssen
  5. MedImmune/AstraZeneca
  6. Novartis
  7. Pfizer
  8. Regeneron
  9. Vitae
  10. Glenmark
  11. Galderma
  12. Asana
  13. Innovaderm
  14. Dermira
  15. UCB
  16. Amgen
  17. Lilly
  18. Merck
  19. Kadmon
  20. Boehringer
  21. Kyowa
  22. BMS
  23. Serono
  24. Biogen Idec
  25. Delenex
  26. Sanofi
  27. Baxter
  28. Paraxel
  29. Xenoport
  30. Kineta

Ask authors/readers for more resources

Background: Peripheral blood skin-homing/cutaneous lymphocyte antigen (CLA)(+) T cells emerge as biomarkers of cutaneous immune activation in patients with inflammatory skin diseases (atopic dermatitis [AD] and alopecia areata [AA]). However, blood phenotyping across these subsets is not yet available in patients with vitiligo. Objective: We sought to measure cytokine production by circulating skin-homing (CLA(+)) versus systemic (CLA(-)) polar'' CD4(+)/CD8(+) ratio and activated T-cell subsets in patients with vitiligo compared with patients with AA, AD, or psoriasis and control subjects. Methods: Flow cytometry was used to measure levels of the cytokines IFN-gamma, IL-13, IL-9, IL-17, and IL-22 in CD4(+)/CD8(+) T cells in the blood of 19 patients with moderate-to-severe nonsegmental/generalized vitiligo, moderate-to-severe AA (n = 32), psoriasis (n = 24), or AD (n = 43) and control subjects (n = 30). Unsupervised clustering differentiated subjects into groups based on cellular frequencies. Results: Patients with Vitiligo showed the highest CLA(+)/CLA(-) T(H)1/type 1 cytotoxic T-cell polarization, with parallel T(H)2/T(H)9/T(H)17/T(H)22 level increases to levels often greater than those seen in patients with AA, AD, or psoriasis (P < .05). Total regulatory T-cell counts were lower in patients with vitiligo than in control subjects and patients with AD or psoriasis (P < .001). Vitiligo severity correlated with levels of multiple cytokines (P < .1), whereas duration was linked with IFN-gamma and IL-17 levels (P < .04). Patients and control subjects grouped into separate clusters based on blood biomarkers. Conclusions: Vitiligo is characterized by a multicytokine polarization among circulating skin-homing and systemic subsets, which differentiates it from other inflammatory/autoimmune skin diseases. Future targeted therapies should delineate the relative contribution of each cytokine axis to disease perpetuation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available